Rare Fatal Disease: This Medical Company Presents Promising Results

PaxMedica's Milestone: A Successful FDA Type-B Meeting and Its Implications for the Future of Rare Disease Treatment.

Clinical-stage biopharmaceutical company, PaxMedica, (NASDAQ: PXMD) recently announced the completion of a crucial FDA Type-B meeting. The company shared promising results from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare but fatal parasitic disease if left untreated (sour…